Company news

Celldex Therapeutics, Inc. news in 2026

Celldex Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

November 5, 2026

Celldex Reports Third Quarter Financial Results and Provides Corporate Update

November 5, 2026

Celldex to Present at Upcoming Investor Conferences

November 4, 2026

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

September 22, 2026

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

August 6, 2026

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

July 21, 2026

Celldex Announces Planned Transition of Chief Financial Officer

July 15, 2026

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

June 14, 2026

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

June 14, 2026

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

June 10, 2026

Celldex Reports First Quarter Financial Results and Provides Corporate Update

May 7, 2026

Celldex to Present at Upcoming Investor Conference

April 13, 2026

Celldex Announces Proposed Public Offering of Common Stock

April 1, 2026

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

March 31, 2026

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

March 26, 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

March 1, 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Dis...

February 28, 2026

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

February 27, 2026

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at...

February 26, 2026

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

February 25, 2026

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

February 25, 2026

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile

February 23, 2026

Decks in 2026